Listen to this page using ReadSpeaker
Archive for the Pharmaceuticals Category

ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease

Dr. Hendrik Scholl at ARVO 2016.Like many diseases affecting the macula, the center of the retina, Stargardt disease is a waste-management problem. The “garbage” comes from the processing of vitamin A, which is an essential nutrient for vision. If you think of the retina as the engine for vision, vitamin A is the fuel; it enables the retina to convert light into the electrical signals that enable vision. And just like gasoline, which produces exhaust, vitamin A, when metabolized, leads to undesirable by-products.
Continue Reading…

Retinal Researchers May Be Looking for You

A patient registers with My Retina Tracker.One of the biggest challenges in overcoming rare retinal diseases is, well, that they’re rare. There’s limited information about the conditions in humans, making it difficult for researchers to understand why they cause blindness and develop vision-saving treatments.
Continue Reading…

2015 Top 10 Retinal-Research Advances

Researcher in a labThe Foundation Fighting Blindness’ scientists, donors and volunteers made 2015 an outstanding year in our fight against blindness. As I tabulated the year’s top 10 research advances—all made possible through FFB funding—I realized that eight are for clinical trials of emerging therapies that are launching or underway.
Continue Reading…

The Gift of Sight – Matched!

Your donation doubledIt’s holiday time, the giving season, when people not only buy gifts for family, friends and co-workers, but also donate to worthy causes—of which there are many. But, if you’ll permit me, I’d like to make a pitch for the Foundation Fighting Blindness (FFB), which happens to be offering a Holiday Board Match, meaning every donation is doubled.
Continue Reading…

The Challenge Continues: FFB Chairman Gordon Gund is Interviewed on CNBC

Gordon Gund on CNBC in NantucketGordon Gund, who’s held in extremely high esteem by people inside and outside the Foundation Fighting Blindness (FFB), has been completely blind for decades. He lost his eyesight to a disease called retinitis pigmentosa in his thirties. Not that it slowed him down much. Among other accomplishments, he’s been a financier, venture capitalist, sports-team owner and sculptor. And, of course, he’s a co-founder of FFB and its chairman of the board.
Continue Reading…

Sun and Funds: FFB’s Annual Summer Campaign

Summer Challenge web pageWe all know that Memorial Day is not, technically, the first day of summer. But seeing as we like to stretch summer out as much as possible, it only makes sense to kick it off… well… a few weeks early. The same premise is behind FFB’s Summer Challenge to End Blindness campaign, which began Memorial Day weekend and continues through the upcoming season.
Continue Reading…

Need-to-Know Information about Clinical Trials

clinical trial patientWith about 15 clinical trials underway for inherited retinal diseases, and several more poised to begin in a few years, patients are eager to sign up for access to potential vision-saving therapies.
Continue Reading…

CME – What It Is, and Why People with Retinal Diseases Should Know About It

Dr. FishmanIn this Q&A, Gerald Fishman, M.D., a world-renowned clinical researcher and longstanding member of FFB’s Scientific Advisory Board, discusses cystoid macular edema (CME), a potentially damaging accumulation of fluid in the retina affecting up to 32 percent of people with retinitis pigmentosa (RP) and related conditions. It’s a complication that can make matters worse for retinas already fragile from degenerative disease. While diagnosis isn’t always straightforward, CME can be treated to minimize vision loss.
Continue Reading…

The Top Research Advancements of 2014: How Fast Can We Go?

lab photoAs we approach 2015, it’s inspiring to look back on 2014 and recount the numerous advancements we’ve made in developing vision-saving treatments and cures. When I joined the Foundation nearly a decade ago, virtually nothing was in a human study. We were curing lots of blind mice, and clinical trials seemed elusive. But, today, more than a dozen promising therapies are being evaluated in people, and at least a dozen more clinical trials are expected to begin in the next few years.
Continue Reading…

A Spice for the Eyes

TumericTurmeric, also known as “the golden spice,” has been around for more than 4,000 years. In India, where Radha Ayyagari, Ph.D., grew up, it’s used widely as both a food spice and an herbal medicine for treating a variety of diseases, including cancer, arthritis, urinary-tract infections and digestive disorders. It has been scientifically established that curcumin, the active ingredient in turmeric, is a potent antioxidant. So it’s perhaps no surprise that Dr. Ayyagari, a professor of ophthalmology at the University of California, San Diego, is developing an extract from turmeric that may be useful in slowing retinal degeneration.
Continue Reading…